Editas Medicine Company Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.

The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.

The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.

Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine, Inc.

Country	United States
Founded	2013
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	246
CEO	Gilmore O’Neill

Contact Details

Address: 11 Hurley Street Cambridge, Delaware 02141 United States
Phone	617 401 9000
Website	editasmedicine.com

Stock Details

Ticker Symbol	0IFK
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US28106W1036
SIC Code	2836

Key Executives

Name	Position
Gilmore O’Neill	Chief Executive Officer
Amy Parison	Chief Financial Officer
Cristi Barnett	Head of Investor Relations